|
||
| |||||||
|
Innate Pharma obtains ISO9001:2000 certification for its research and development activity in the field of immunotherapy
Marseille, September 2, 2005 - Innate
Pharma, a leading developer of novel anti-tumoral therapies, announced today
that it has received ISO9001:2000 certification for its research and
development activity in the field of immunotherapy.
This certification marks a new milestone in Innate Pharma's development and occurs at a time when the company is significantly building up its team, enlarging its portfolio of compounds and working on a number of new industry partnerships. "The ISO9001:2000 certification is undoubtedly a major step forward in Innate Pharma's path to becoming a mature company," said Hervé Brailly, CEO at Innate Pharma. "It will be a key asset in winning future industrial and commercial contracts with the pharmaceutical industry."
"European biotechnology companies that have sought
and obtained this certification are few and far between," said Jacques Beslin,
Managing Director of the French certification body AFAQ AFNOR. "Innate Pharma
can be proud of having been through the certification procedure successfully.
The award confirms the company's ability to compete on a global scale and that
it achieves the tough quality criteria defined by the ISO standard."
About Innate Pharma:
www.innate-pharma.com
Innate Pharma S.A.S., is a French
biopharmaceutical company specialized in cancer immuno-therapeutics. It is the
first company to develop immuno-modulating agents targeting non-conventional
lymphocytes. The company already has several drug candidates in clinical
development, including two products in Phase I of clinical development in
cancer. The company was founded in 1999, and has raised EUR40 million in
private funding since its inception in three rounds of financing. Companies
investing in Innate are Novo-Nordisk (Copenhagen), NIF (Tokyo), Quilvest
(Paris), Sofinnova Partners (Paris), Alta Partners (San Francisco), GIMV (Anvers),
Auriga Partners (Paris), Axa Private Equity (Paris), Gilde Biotech & Nutrition
(Utrecht), Pechel Industries (Paris), Innoveris (Marseille) et
Inserm-Transfert (Paris). Based in Marseille, Innate Pharma employs 50 staff.
|
|
| ||||||||